Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010:59:197-233.
doi: 10.1016/S1054-3589(10)59007-0.

Advances in the renin angiotensin system focus on angiotensin-converting enzyme 2 and angiotensin-(1-7)

Carlos M Ferrario  1 , Sarfaraz Ahmad, Janae Joyner, Jasmina Varagic
Affiliations

Advances in the renin angiotensin system focus on angiotensin-converting enzyme 2 and angiotensin-(1-7)

Carlos M Ferrario et al. Adv Pharmacol. 2010.

Abstract

The contribution of the renin angiotensin system to physiology and pathology is undergoing a rapid reconsideration of its mechanisms from emerging new concepts implicating angiotensin-converting enzyme 2 and angiotensin-(1-7) as new elements negatively influencing the vasoconstrictor, trophic, and pro-inflammatory actions of angiotensin II. This component of the system acts to oppose the vasoconstrictor and proliferative effects on angiotensin II through signaling mechanisms mediated by the mas receptor. In addition, a reduced expression of the vasodepressor axis composed by angiotensin-converting enzyme 2 and angiotensin-(1-7) may contribute to the expression of essential hypertension, the remodeling of heart and renal function associated with this disease, and even the physiology of pregnancy and the development of eclampsia.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest Statement: There are no conflicts of interest to disclose.

Figures

FIGURE 1
FIGURE 1
Schematic diagram of the key biochemical steps involved in the formation of angiotensin peptides.
See this image and copyright information in PMC

References

    1. Agata J, Ura N, Yoshida H, Shinshi Y, Sasaki H, Hyakkoku M, et al. Olmesartan is an angiotensin II receptor blocker with an inhibitory effect on angiotensin-converting enzyme. Hypertension Research. 2006;29:865–874. - PubMed
    1. Alenina N, Xu P, Rentzsch B, Patkin EL, Bader M. Genetically altered animal models for mas and angiotensin-(1–7) Experimental Physiology. 2008;93:528–537. - PubMed
    1. Alfany-Fernandez I, Casillas-Ramirez A, Bintanel-Morcillo M, Brosnihan KB, Ferrario CM, Serafin A, et al. Therapeutic targets in liver transplantation: Angiotensin II in nonsteatotic grafts and angiotensin-(1–7) in steatotic grafts. American Journal of Transplantation. 2009;9:439–451. - PubMed
    1. Almeida AP, Frabregas BC, Madureira MM, Santos RJ, Campagnole-Santos MJ, Santos RA. Angiotensin-(1–7) potentiates the coronary vasodilatatory effect of bradykinin in the isolated rat heart. Brazilian Journal of Medical and Biological Research. 2000;33:709–713. - PubMed
    1. Altundag K, Altundag O, Akyurek S, Silay K, Turen S. Angiotensin 1–7 and risk for breast cancer recurrence. Cancer Chemotherapy Pharmacology. 2006;58:283. - PubMed

Publication types

MeSH terms

LinkOut - more resources